Form 4: Bristol-Myers Squibb Director Boosts DSU Holdings

Bristol-Myers Squibb Director Michael R. McMullen increased his beneficial ownership of Deferred Share Units by 776.053 units on September 30, 2025, as part of a pre-arranged plan.

Summary

• Michael R. McMullen, a Director of Bristol-Myers Squibb Company (BMY), acquired 776.053 Deferred Share Units (DSUs).
• The transaction date for the acquisition was September 30, 2025.
• The acquisition was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged contract or instruction for the purchase of equity securities.
• Following this transaction, Michael R. McMullen beneficially owns a total of 10,076.278 Deferred Share Units.
• Each Deferred Share Unit will convert into one share of common stock upon settlement, which occurs when the reporting person ceases to be a director or at a previously specified future date.
• The price of the derivative security (DSU) was $0, typical for units granted as compensation.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as a director increasing their beneficial ownership, even through compensation, generally signals confidence and aligns interests with shareholders. The transaction is routine and expected, preventing a higher score.

Positives

• The acquisition of Deferred Share Units by a director indicates continued alignment of management's interests with those of shareholders, as the value of these units is tied to the company's stock performance.
• The transaction being executed under a Rule 10b5-1 plan suggests a systematic and pre-planned approach to compensation or equity accumulation, rather than a reactive market-timing decision.

Future Outlook

The Deferred Share Units acquired by Michael R. McMullen are scheduled to settle and convert into common stock upon his cessation as a director or at a future date he previously specified, providing a future equity stake.

Industry Context

This transaction is a routine insider filing related to executive compensation, common across the pharmaceutical industry. Deferred Share Units are a standard component of long-term incentive plans for directors and executives, designed to align their interests with shareholder value creation over time.

Stakeholder Impact

• Shareholders: The acquisition of DSUs by a director enhances alignment between management and shareholder interests, as the director's future compensation is tied to the company's stock performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Settlement of the Deferred Share Units into common stock upon Michael R. McMullen ceasing to be a director or at a pre-specified future date.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-planned acquisition of Deferred Share Units by a director as part of their compensation. While it indicates alignment of interests, it does not present new fundamental information or significant changes to the company's financial outlook or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Bristol-Myers Squibb, BMY, Michael R. McMullen, Director, Deferred Share Units, DSU, Insider Transaction, Form 4, Equity Compensation, Rule 10b5-1